Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.

Marie-Rose Peeters,Timothy Jay Price,Andrew Strickland,Tudor-Eliade Ciuleanu,Werner Scheithauer,Seamus O'Reilly,M. Keane,David R. Spigel,Ying Tian,K. Krishnan

Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.

2011

Marie-Rose Peeters
Timothy Jay Price
Andrew Strickland
Tudor-Eliade Ciuleanu
Werner Scheithauer
Seamus O'Reilly
M. Keane
David R. Spigel
Ying Tian
K. Krishnan

3574^ Background: Pmab, a fully human monoclonal antibody targeting EGFR, has demonstrated activity in combination with FOLFIRI for second-line treatment of mCRC (study 181). Here, we describe the ...

Keywords:

Fluorouracil
FOLFIRI
Bevacizumab
Colorectal cancer
Physical therapy
Subgroup analysis
Cancer research
Panitumumab
Irinotecan
Medicine
Oncology
Internal medicine
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations